Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Cash & Equivalents readings, the most recent being $190.0 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 29.21% to $190.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $190.0 million, a 29.21% decrease, with the full-year FY2025 number at $165.6 million, down 9.8% from a year prior.
  • Cash & Equivalents hit $190.0 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $165.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $268.3 million in Q1 2025 to a low of $80.6 million in Q1 2023.
  • Median Cash & Equivalents over the past 5 years was $174.9 million (2025), compared with a mean of $167.2 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 44.86% in 2022 and later surged 94.34% in 2024.
  • Kiniksa Pharmaceuticals International's Cash & Equivalents stood at $122.7 million in 2022, then dropped by 12.03% to $108.0 million in 2023, then skyrocketed by 70.05% to $183.6 million in 2024, then decreased by 9.8% to $165.6 million in 2025, then increased by 14.71% to $190.0 million in 2026.
  • The last three reported values for Cash & Equivalents were $190.0 million (Q1 2026), $165.6 million (Q4 2025), and $174.9 million (Q3 2025) per Business Quant data.